Global Locally Advanced Pancreatic Cancer Market - 2025-2033

The global locally advanced pancreatic cancer market size reached US$ 1.31 billion in 2024 and is expected to reach US$ 2.38 billion by 2033, growing at a CAGR of 7.0% during the forecast period 2025-2033.

Locally advanced pancreatic cancer refers to a stage of pancreatic cancer where the tumor is confined to the pancreas and the surrounding areas but has not spread to distant organs like the liver, lungs, or distant lymph nodes. In this stage, the cancer has grown locally and may involve nearby blood vessels, nerves or structures, making it difficult to remove surgically.

The cancer may extend to adjacent structures such as the duodenum, bile ducts, spleen and large blood vessels (such as the superior mesenteric artery or the portal vein), which can make surgery risky or infeasible. Despite the cancer being confined to the local area, it is often considered "unresectable" at this stage because the tumor's involvement with nearby blood vessels or nerves means complete surgical removal is not possible without risking severe complications.

The management of locally advanced pancreatic cancer usually involves a combination of chemotherapy, radiation therapy and in some cases, targeted therapy or immunotherapy. Surgery might be an option in rare cases if the tumor shrinks significantly after treatment, allowing it to become resectable.

Market Dynamics: Drivers & Restraints

The rising demand for advanced therapies is significantly driving the locally advanced pancreatic cancer market growth

Locally advanced pancreatic cancer is often diagnosed at an advanced stage, and traditional chemotherapy treatments have limitations, prompting the need for innovative therapies that can target the disease more precisely and effectively. It is a general practice to enroll patients in ongoing clinical trials to improve their overall survival.

Several clinical trials are currently ongoing which are evaluating a plethora of treatment options for locally advanced pancreatic cancer, and are showing promising results. For instance, immune checkpoint inhibitors like nivolumab (Opdivo) and pembrolizumab (Keytruda) are being tested for their potential to treat locally advanced pancreatic cancer. These therapies work by boosting the immune system to recognize and attack cancer cells, showing promise in clinical trials for pancreatic cancer.

Additionally, in December 2024, Novocure announced that the pivotal Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.

Moreover, Peking Union Medical College Hospital in China is currently evaluating the safety and efficacy of Nimotuzumab in combination with FOLFIRINOX for the treatment of locally advanced pancreatic cancer. The study is in Phase II trials evaluating parameters such as overall survival rate, progression free survival, objective response rate etc.

The demand for these advanced therapies is growing as they offer the potential for longer overall survival and better quality of life for locally advanced pancreatic cancer patients. There are several such advanced therapies currently in clinical development and are showing promising results in locally advanced pancreatic cancer treatment.

Limited efficacy of current therapies hampering the market growth

Despite advances in treatment, this type of pancreatic cancer remains one of the most difficult cancers to treat due to its aggressive nature, late-stage diagnosis and resistance to many therapies. However, chemotherapy stands as a major therapy option for the condition, whose efficacy is limited in the majority of the patient population, and a recurrence is expected in most of them.

For instance, the standard treatment for LAPC often includes FOLFIRINOX gemcitabine, nab-paclitaxel, etc. While this regimen improves survival compared to monotherapies, it is still only effective for a portion of patients, prolonging the survival rate to a mere extent.

Additionally, immune checkpoint inhibitors, like nivolumab and pembrolizumab were considered promising but, further trials have to be conducted to evaluate their efficacy, and if they can prolong the overall survival rate as compared with the current therapies. Radiation therapy is often used in combination with chemotherapy for LAPC, but its effectiveness is limited by factors such as the tumor's proximity to vital organs and its resistance to radiation.

Segment Analysis

The global locally advanced pancreatic cancer market is segmented based on therapy, end-user and region.

Therapy:

The chemotherapy segment is expected to dominate the locally advanced pancreatic cancer market with the highest market share

Chemotherapy is a drug treatment that essentially kills cells, especially the fast-growing cancer cells, and inhibits their rapid growth and multiplication. Various chemotherapy drugs could be used either alone or in combination to treat different types of cancers. The most common chemotherapy drugs used in locally advanced pancreatic cancer are Gemcitabine, Folfirinox, Nab-Paclitaxel, Cisplatin and others.

At present, chemotherapy stands as a major therapeutic option for locally advanced pancreatic cancer, with many health governing bodies recommending them as first-line treatment options in LAPC. These drugs shrink the tumor size making it convenient for surgical resection.

As per the National Comprehensive Cancer Network (NCCN) guidelines, the standard of care for LAPC includes FOLFIRINOX or modified FOLFIRINOX, or Gemcitabine + nab-paclitaxel. According to the European Society for Medical Oncology (ESMO) guidelines, The first-line therapy for LAPC includes either FOLFIRINOX or Gemcitabine + nab-paclitaxel.

Additionally, according to the Japan Pancreas Society Practice Guidelines 2022, the first-line treatment for LAPC includes chemotherapy with FOLFIRINOX or Gemcitabine + nab-paclitaxel, or Gemcitabine monotherapy. Chemotherapy is practiced across the world as the first line of care, due to its efficacy as compared to other treatment options, and its capability to improve the overall survival rate in LAPC patients.

Geographical Analysis

North America is expected to hold a significant position in the global locally advanced pancreatic cancer market with the highest market share

The locally advanced pancreatic cancer market in the North America region is expected to grow owing to the strong presence of major market players, the rising prevalence of pancreatic cancers, increasing research activities, rising awareness about cancer, rising clinical studies and well-established healthcare infrastructure are the factors expected to drive the market in the region.

The prevalence of pancreatic cancer in the United States is continuously rising which further increases the demand for treatment options. Factors such as aging populations, lifestyle changes and the prevalence of risk factors like obesity and smoking are driving the demand for improved treatments. For instance, the American Cancer Society's estimates for pancreatic cancer in the United States for 2024 are that about 66,440 people (34,530 men and 31,910 women) will be diagnosed with pancreatic cancer and about 51,750 people (27,270 men and 24,480 women) will die of pancreatic cancer.

Moreover, in November 2024, Northwell Health Cancer Institute joined RenovoRx's Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer. The trial evaluates RenovoRx's TAMP therapy platform, comparing intra-arterial gemcitabine delivery via the FDA-cleared RenovoCath system to standard intravenous chemotherapy. The study aims to complete enrollment in the first half of 2025.

Competitive Landscape

Top companies in the locally advanced pancreatic cancer market includes F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd, Merus N.V., Pfizer Inc., Fresenius Kabi AG, BRISTOL-MYERS SQUIBB COMPANY, CHEPLAPHARM Arzneimittel GmbH and Bayer AG among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global locally advanced pancreatic cancer market report delivers a detailed analysis with 54 key tables, more than 44 visually impactful figures and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.